๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Significance of pretreatment hemoglobin level in patients with T1 glottic cancer

โœ Scribed by Daniel J. Canaday; William F. Regine; Mohammed Mohiuddin; William Zollinger; Mitchell Machtay; Jason Lee; Delray Schultz; Marc S. Rudoltz


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
147 KB
Volume
7
Category
Article
ISSN
1065-7541

No coin nor oath required. For personal study only.

โœฆ Synopsis


Recent reports have suggested that pretreatment hemoglobin level (Hgb) is significantly associated with local control (LC) and overall survival (OS) in patients with T1 and T2 squamous cell carcinoma of the glottic larynx. To further evaluate the association of pretreatment Hgb level and other factors with outcome, we performed a retrospective review limited to patients with T1 squamous cell carcinoma of the glottic larynx treated with external beam radiation therapy. One-hundred thirty-nine patients with T1 squamous cell carcinoma of the glottic larynx were analyzed. Median follow-up was 5 years (range 2-22). Median pretreatment Hgb was 14.4 gm/dl (range 8.2-17.2). The following parameters were analyzed for their impact on LC, OS, and disease specific survival (DSS): age; gender; pretreatment Hgb; tumor grade; anterior commissure involvement; field size; total dose; dose per fraction; and overall treatment time. Five-year actuarial LC was 84%. Pretreatment Hgb was not a significant predictor for LC when assessed as a continuous variable (P = 0.38), nor as a dichotomous variable with a cutoff at 13 gm/dl. Local control was 82% for patients with Hgb >13 vs. 92% for Hgb เด› 13 (P= 0.13). No other factor was significant for LC. Five-year actuarial OS was 74%. Univariate analysis revealed that, pretreatment Hgb, total dose, and patient age were significant factors for OS. Overall survival was 78% for patients with pretreatment Hgb > 13 gm/dl vs. 68% for patients with Hgb เด› 13 gm/dl (P = 0.004). Overall survival was 77% for patients treated with > 66 Gy vs. 67% for those treated with เด›66 Gy (P = 0.0013), and 80% for patients เด›61 years as opposed to 69% for patients older than 61 years (P = 0.017). Multivariate analysis revealed that only age (P = 0.014) and Hgb concentration (P = 0.001) retained significance. Five-year actuarial DSS was 92%. Pretreatment Hgb was not a prognostic factor for DSS, nor were any other analyzed factors. Pretreatment Hgb is not a significant prognostic factor for LC in patients with T1 squamous cell carcinoma of the glottic larynx, but it does predict for a poorer OS without affecting DSS. This suggests that patients with lower pretreatment Hgb may have confounding medical problems that detract from their overall survival.


๐Ÿ“œ SIMILAR VOLUMES


Cancer risk in patients with monoclonal
โœ Gregersen, Henrik; Mellemkj๏ฟฝr, Lene; Salling Ibsen, Jenna; S๏ฟฝrensen, Henrik Toft ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 40 KB ๐Ÿ‘ 2 views

To assess the cancer risk of monoclonal gammopathy of undetermined significance (MGUS) we identified 1229 cases of MGUS in the period 1978 to 1993. Data on cancer occurrence in the MGUS cohort were obtained from the Danish Cancer Registry. The expected numbers of cancer cases were calculated from ag

Molecular detection of low-level disease
โœ Burchill, Susan A.; Selby, Peter J. ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 202 KB ๐Ÿ‘ 2 views

The accurate detection of low-level disease in patients with cancer is essential to improve the staging of disease and consequently to deยฎne appropriate treatment strategies. Most methods currently used for staging are based on imaging studies and histological and immunocytochemical analysis of tiss

High levels of tissue inhibitor of metal
โœ Kevin McCarthy; Teresa Maguire; Gerald McGreal; Enda McDermott; Niall O'Higgins; ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 67 KB ๐Ÿ‘ 2 views

Studies from model systems suggest that matrix metalloproteinases (MMPs) are causally involved in tumor progression while tissue inhibitors of MMPs (TIMPs) prevent this progression. Here, we show that concentrations of TIMP-1 are significantly higher in breast carcinomas than in fibroadenomas. In pr